14th Jan 2020 09:00
(Alliance News) - Clinigen Group PLC said Tuesday it has inked an agreement with US late stage biotechnology company Iovance Biotherapeutics Inc for the supply of proleukin.
Iovance is current undertaking studies of its tumour infiltrating lympocyte technology for the treatment of metastatic melanoma and advanced cervical cancer.
In addition, this therapy is being investigated for the treatment of patients with locally advanced, recurrent or metastatic cancers, including head and neck and non-small cell lung cancer.
Proleukin is part of the therapy treatment regimen being studied.
Proleukin is for the treatment of adults with metastatic renal cell carcinoma or metastatic melanoma. Proleukin will be made available by Clinigen in bulk supply over the course of a two-year period. Neither Clinigen or Iovance disclosed any financial details about the contract.
"Clinigen is committed to getting the right medicine to the right patient at the right time. This agreement demonstrates our unwavering commitment to our mission for patients while also bringing synergistic opportunities to other businesses within the Clinigen Group - in this case, to Clinical Services as we supply Proleukin for use in Iovance's future clinical trials," said Chief Executive Officer Shaun Chilton.
Shares in Clinigen - which is headquartered in Staffordshire - were up 1.3% at 919.00 pence on Tuesday in London.
By Dayo Laniyan; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
CLIN.L